Jahan R, Duckwiler G R, Kidwell C S, Sayre J W, Gobin Y P, Villablanca J P, Saver J, Starkman S, Martin N, Vinuela F
Department of Radiological Sciences, UCLA School of Medicine, Los Angeles, CA 90095, USA.
AJNR Am J Neuroradiol. 1999 Aug;20(7):1291-9.
Since the approval of intravenous tissue plasminogen activator for acute ischemic stroke, great interest has been generated in cerebral fibrinolysis. Our purpose was to assess long-term outcome and hemorrhagic risk in patients with anterior circulation ischemic stroke treated with intraarterial urokinase.
Twenty-six patients were treated within 6 hours of ictus; of these, 21 were followed up for an average of 23 months. Angiographic reperfusion was classified according to thrombolysis in myocardial infarction (TIMI) grades. The Rankin Scale (RS) and the modified Barthel Index (mod BI) were used as outcome measures (good outcome: RS = 0-2, mod BI = 16-20; poor outcome: RS = 3-5, mod BI < or = 15).
Ten of the 21 patients (average age, 48 years) had a good outcome; three (average age, 71 years) had a poor outcome; eight patients (average age, 78 years) died. Partial/complete (successful) recanalization was observed in 11 of 26 patients and minimal or no (unsuccessful) recanalization in 15. Recanalization favored a better outcome: nine of 21 had successful recanalization, with a good outcome in seven; 12 of 21 had unsuccessful reperfusion, with poor outcome/death in nine. Poor outcome was noted in five patients with internal carotid artery (ICA) bifurcation occlusions, four of whom had unsuccessful recanalization and poor outcome or death. Hemorrhage occurred in 10 of the 26 patients, with clinical deterioration in three. The average dose of urokinase was higher in the hemorrhage group, and mortality was higher in patients who hemorrhaged.
Intraarterial thrombolysis is feasible in the setting of acute stroke. Successful reperfusion is associated with a better outcome, and the prevalence of hemorrhage does not exceed that which occurs in the natural history of embolic stroke. Poor outcome or death is associated with nonrecanalization, older age, hemorrhage, and ICA bifurcation occlusions.
自从静脉注射组织型纤溶酶原激活剂被批准用于急性缺血性卒中以来,脑纤维蛋白溶解疗法引起了人们极大的兴趣。我们的目的是评估接受动脉内尿激酶治疗的前循环缺血性卒中患者的长期预后及出血风险。
26例患者在发病6小时内接受治疗;其中21例患者平均随访23个月。血管造影再通情况根据心肌梗死溶栓(TIMI)分级进行分类。采用Rankin量表(RS)和改良Barthel指数(mod BI)作为预后指标(良好预后:RS = 0 - 2,mod BI = 16 - 20;不良预后:RS = 3 - 5,mod BI≤15)。
21例患者(平均年龄48岁)中有10例预后良好;3例(平均年龄71岁)预后不良;8例患者(平均年龄78岁)死亡。26例患者中有11例观察到部分/完全(成功)再通,15例为轻微或无(不成功)再通。再通有利于更好的预后:21例中有9例成功再通,其中7例预后良好;21例中有12例再灌注不成功,其中9例预后不良/死亡。5例颈内动脉(ICA)分叉闭塞患者预后不良,其中4例再通不成功且预后不良或死亡。26例患者中有10例发生出血,3例出现临床病情恶化。出血组尿激酶平均剂量更高,出血患者的死亡率更高。
动脉内溶栓在急性卒中情况下是可行的。成功再灌注与更好的预后相关,出血发生率不超过栓塞性卒中自然病程中的发生率。预后不良或死亡与未再通、高龄、出血及ICA分叉闭塞有关。